3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
28
Lymphoma, Mantle-Cell
14
Lymphoma, Non-Hodgkin
8
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma
5
Leukemia, B-Cell
4
Multiple Myeloma
3
Lymphoma, B-Cell
3
Waldenstrom Macroglobulinemia
2
Recurrence
2
Pancreatic Neoplasms
2
Lymphoma, Follicular
2
Lymphatic Diseases
2
Leukemia, Prolymphocytic
2
Leukemia
2
Squamous Cell Carcinoma of Head and Neck
1
Part1: Advanced B-cell Malignancies
1
Ovarian Neoplasms
1
Neoplasms
1
Lymphoproliferative Disorders
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Hairy Cell
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Heart Failure
1
Glioblastoma
1
DLBCL
1
Interventions
Azacitidine
14
venetoclax
10
AP 1903 reagent
7
Rituximab
6
Dexamethasone
6
Itraconazole
5
Cytarabine
5
Bortezomib
5
fludarabine
4
fedratinib
4
belinostat
4
Nivolumab
4
Lenalidomide
4
Imatinib Mesylate
4
Daunorubicin
4
ARQ531
4
pomalidomide
3
ibrutinib
3
daratumumab
3
cc-486
3
angiotensin I (1-7)
3
Standard of Care
3
GSK2110183
3
Cyclophosphamide
3
zanubrutinib
2
tosedostat
2
tazemetostat
2
tanespimycin
2
talquetamab
2
tafasitamab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Hematologic Neoplasms
×
acalabrutinib
×
Clear all
NCT05205252
2023-08-15
ARIA
Ipsen
Phase 1/2
Withdrawn